ArticleCureus2025
Anti-TIF1-Gamma Autoantibodies-Positive Juvenile Dermatomyositis Associated With Interstitial Lung Disease: A Case Report.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Rituximab for Early-Onset Juvenile Dermatomyositis Complicated by Interstitial Lung Disease.Case reports in pediatrics · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Juvenile dermatomyositis (JDM) is a rare autoimmune disease in children, characterized by muscle inflammation and skin manifestations. This case report describes a nine-year-old boy with JDM associated with anti-TIF1-γ antibodies and interstitial lung disease (ILD). The patient presented with progressive muscle weakness and characteristic skin lesions. Imaging confirmed ILD, and treatment with methylprednisolone pulses and rituximab resulted in significant improvement. This case emphasizes the need for pulmonary monitoring in JDM patients, regardless of antibody profile, and highlights the importance of personalized treatment approaches.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.